MB-101 demonstrated a high safety profile and significant therapeutic potential in treating patients with recurrent and refractory malignant glioma, including those with glioblastoma.

Vaxxinity, Inc., a biopharmaceutical firm listed on NASDAQ under the ticker VAXX, has reported encouraging clinical trial outcomes for its UB-312 drug candidate

NodThera has announced the successful results of a Phase Ib/IIa clinical trial for its NLRP3 inflammasome inhibitor, NT-0796.

Novo Nordisk has announced encouraging results from its Phase I clinical trial for a novel obesity treatment, amycretin, at its Capital Markets Day event.

Kiora Pharmaceuticals has revealed findings from a Phase 1 double-blind study involving KIO-101, a strong, non-steroidal anti-inflammatory drug.

Acumen Pharmaceuticals presented cerebrospinal fluid (CSF) biomarker data from its Phase 1 INTERCEPT-AD trial of sabirnetug (ACU193).

Kyverna Therapeutics has entered into a collaboration with Stanford University to conduct a phase 1 investigator-initiated trial (IIT) of KYV-101.

Preclinical studies indicate that ARO-DM1 effectively reduces muscular DMPK expression and alleviates spliceopathies, potentially enhancing muscle strength and function.

A cutting-edge treatment for hair loss has been developed by Pelage Pharmaceuticals, a company at the forefront of regenerative medicine.

Ranok Therapeutics has commenced a Phase 1 clinical trial in China for RNK05047, its first protein degrader candidate.

Journey Medical Corporation announced positive results from their Phase 1 clinical trial of DFD-29, aimed at treating rosacea.

ImmunAbs has achieved milestone success by completing Phase 1 clinical trials for their new antibody therapeutic, IM-101.